Document Detail

Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
MedLine Citation:
PMID:  22853866     Owner:  NLM     Status:  MEDLINE    
Gefitinib and erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), are widely used anticancer drugs for patients with non-small cell lung cancer (NSCLC), especially for those with EGFR-activating mutations. Both agents are considered to be less toxic compared with cytotoxic drugs; however, serious adverse events including interstitial lung disease (ILD) which can be fatal occur rarely. After such an event, physicians avoid to use another TKI. In such cases, patients and physicians are forced to make difficult decisions or reluctantly choose TKI when there is no other option. Here we report a case of a patient with lung adenocarcinoma who showed good recovery from gefitinib-induced ILD by high-dose corticosteroid therapy. The patient was then administrated erlotinib as second-line chemotherapy and showed tumor shrinkage without ILD after 6 months of treatment. We discuss the common features of the cases in the previous documentations and ours which were successfully retreated with erlotinib after gefitinib-induced ILD had previously developed.
Yasuko Koma; Hirofumi Matsuoka; Harukazu Yoshimatsu; Yujiro Suzuki
Related Documents :
622636 - Retropharyngeal abscess after endoscopic retrograde cholangiopancreatography: an uncomm...
16824236 - Tonsillitis to mediastinitis.
8148296 - Blister formation on the thumb following the second intravenous regional reserpine in t...
25183456 - Sarcoidosis of the head and neck.
2640516 - Mediastinal and pulmonary entomophthoromycosis with superior vena cava syndrome: case r...
11444786 - Etiology and outcome of hydrops fetalis.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  50     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-17     Completed Date:  2012-11-13     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  760-4     Citation Subset:  IM    
Department of Respiratory Medicine, Shinko Hospital, Kobe, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / drug therapy*
Lung Diseases, Interstitial / chemically induced*
Lung Neoplasms / drug therapy*
Middle Aged
Protein Kinase Inhibitors / therapeutic use*
Quinazolines / adverse effects*,  therapeutic use*
Reg. No./Substance:
0/Protein Kinase Inhibitors; 0/Quinazolines; J4T82NDH7E/erlotinib; S65743JHBS/gefitinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
Next Document:  Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following ora...